Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yuhan
Pharma
Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia
In two deals potentially worth $2 billion each, Novo gained a "triple G" candidate from United Labs as Merck bought a CV asset from Hengrui.
Angus Liu
Mar 28, 2025 9:28am
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Jan 10, 2025 9:00am
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Oct 18, 2024 8:20am
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
Sep 27, 2024 10:15am
Gilead, Yuhan ink $81M HIV API supply pact
Sep 20, 2024 11:20am
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
